Azaindole derivatives as inhibitors of protein kinases

Compound of the following formula (I):

• characterized in that,
• R1 is a C1-C6 alkyl group,
• X is CH2 or C═O,
• R2 is hydrogen atom, an alkyl group or a halogen atom,
• Y is chosen from a group consisting of HNC(O), HNC(S), HNSO2, HNC(O)CH2, HNC(O)NH, HNC(S)NH, C(O)NH, C(O)NHCH2, CH2NHC(O) and CH2NHC(S), and
• R3 is chosen from a group consisting of:
• a phenyl group mono or polysubstituted with:
• a hydroxyl,
• a halogen,
• a C1-C6 alkyl-amine,
• a C1-C6 alkoxy,
• a C1-C6 trifluoroalkoxy,
• a C1-C6 alkyl,
• a C1-C6 trifluoroalkyl,
• a heteroaryl fragment optionally substituted with a C1-C6 alkyl, a C1-C6 trifluoroalkyl, a halogen and/or a hydroxyl, wherein said heteroaryl fragment is chosen from a group consisting of dihydrobenzofuran, indol, benzodioxol, benzotriazol, pyridine or a thiazol,
• an imidazole, with the proviso that Y is HNC(S), HNSO2, HNC(O)CH2, HNC(O)NH, HNC(S)NH, C(O)NHCH2, CH2NHC(O), CH2NHC(S) or C(O)NH wherein NH is directly linked to R3,
• a heteroaryl group,
• non aromatic monosubstituted cyclic group, and
• a fragment chosen from a group consisting of:
• and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof.